NMRA (Neumora Therapeutics Inc.) stock: $0.73, $137.2M market cap, $116.8M cash, $73.3M EV, $175.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
navacaprant
Phase 3 · Terminated Modality: small molecule (oral)
Target kappa opioid receptor (KOR)
Partnerships The Scripps Research Institute (TSRI; exclusive license via BlackThorn acquisition)
Indications- Major depressive disorder (MDD) (Phase 3)
Status note Kappa opioid receptor antagonist investigated in the KOASTAL pivotal Phase 3 program in moderate to severe MDD. Following Phase 3 KOASTAL program results in June 2026, the company is discontinuing development of navacaprant in MDD.
NMRA-511
Phase 1 · Active Modality: small molecule (oral)
Target vasopressin 1a receptor (V1aR)
Partnerships The Scripps Research Institute (TSRI; exclusive license via BlackThorn acquisition)
Indications- Alzheimer's disease agitation (Phase 1)
Catalysts- — second half of 2026
- — first quarter of 2027
Status note V1aR antagonist. Phase 1b results reported Q1 2026; MAD expansion cohort evaluating higher doses expected to report data H2 2026.
NMRA-898
Phase 1 · Active Modality: small molecule (oral)
Target muscarinic acetylcholine receptor M4 (M4 PAM)
Partnerships Vanderbilt University (exclusive worldwide license; Warren Center for Neuroscience Drug Discovery)
Status note M4 muscarinic receptor positive allosteric modulator; Phase 1 MAD study ongoing.
NMRA-861
Stage not disclosed · Active Modality: small molecule
Target muscarinic acetylcholine receptor M4 (M4 PAM)
Partnerships Vanderbilt University (exclusive worldwide license)
Indications- Neuropsychiatric disorders (Stage not disclosed)
Status note M4 muscarinic receptor positive allosteric modulator; part of the M4 franchise with NMRA-898.
NMRA-215
Stage not disclosed · Active Modality: small molecule (oral)
Target NLRP3
Indications- Obesity (Stage not disclosed)
- Cardiovascular risk (Stage not disclosed)
Status note Oral NLRP3 inhibitor.
NMRA-GCase
Preclinical · Active
Target glucocerebrosidase (GCase)
Partnerships Amgen (exclusive worldwide license to compounds directed to glucocerebrosidase)
Indications- Neurodegenerative diseases (Preclinical)
Status note Preclinical program directed to glucocerebrosidase for neurodegenerative diseases.
NMRA-CK1δ
Stage not disclosed · Active Modality: small molecule
Target casein kinase 1 delta (CK1δ)
Partnerships Amgen (exclusive worldwide license to compounds directed to casein kinase 1 delta)
Indications- Amyotrophic lateral sclerosis (ALS) (Stage not disclosed)
Status note Program directed to CK1 delta for TDP-43-driven pathology.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.